anlotinib + gemcitabine + cisplatin

Anlotinib + gemcitabine + cisplatin is a combination regimen consisting of three drugs used primarily in oncology. Anlotinib is a small molecule multi-targeted tyrosine kinase inhibitor that blocks angiogenesis and tumor cell proliferation by inhibiting receptors such as VEGFR, FGFR, PDGFR, and c-Kit. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, leading to apoptosis in rapidly dividing cells. Cisplatin is a platinum-based chemotherapeutic agent that causes DNA crosslinking and subsequent cell death. This combination has been investigated as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) and advanced biliary tract cancer (BTC), showing promising efficacy with manageable safety profiles[1][2][4]. The regimen leverages the antiangiogenic effects of anlotinib alongside the cytotoxic actions of gemcitabine and cisplatin.